AceView offers a comprehensive annotation of human, mouse and nematode genes
reconstructed by co-alignment and clustering of all publicly available
mRNAs and ESTs on the genome sequence. Our goals are to offer a reliable
up-to-date resource on the genes, their functions, alternative variants,
expression, regulation and interactions, in the hope to stimulate
further validating experiments at the bench
This site normally requires a frame enabled viewer,
However, click here to access our full description of gene HNRPLL.
, go to our main page or see our latest news
Homo sapiens gene HNRPLL, encoding heterogeneous nuclear ribonucleoprotein L-like.
TABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Compact gene diagram
Alternative mRNAs are shown aligned from 5' to 3' on a virtual genome where introns have been shrunk to a minimal length. Exon size is proportional to length, intron height reflects the number of cDNAs supporting each intron. Introns of the same color are identical, of different colors are different. 'Good proteins' are pink, partial or not-good proteins are yellow, uORFs are green. 5' cap or3' poly A flags show completeness of the transcript.
Read more...
Mouse over the ending of each transcript gives tissues from which the supporting cDNAs were extracted. Details on tissue of origin for each intron and exon is available from the
intron and exons table.
Click on any transcript to open the specific mRNA page, to see the exact cDNA clone support and eventual SNPs and to get details on tissues, sequences, mRNA and protein annotations. Proteins supported by a single continuous cDNA sequence lead to underlining the name/ending of the variant. Names not underlined result from cDNA concatenation in the coding region and should be experimentally checked.
Introns are depicted by broken lines; the height of the top of each intron reflects the relative number of clones supporting this intron.
]^[ A pink broken line denotes an intron with standard boundaries (gt-ag or gc-ag) that is exactly supported (i.e. a cDNA sequence exactly matches the genome over 16 bp, 8 on both sides of the intron).
] ^ ] A blue broken line denotes non-standard introns, exactly supported, but with non-standard at-ac or any other boundaries.
]-[ Pink and
] - ] blue straight lines represent 'fuzzy' introns of the standard and non-standard types respectively, those introns do not follow the 16 bp rule. Black straight lines ]-[denote gaps in the alignments.
Exons: Wide filled pink areas represent putative protein coding regions, narrow empty pink boxes represent the 5'UTR (on the left) and 3' UTR (on the right). Flags identify validated endings: cap site on the 5' side, polyadenylation site on the 3' side. Filled flags correspond to frequent events while empty flags have lesser supporting cDNAs (yet all are validated); at the 3' side, black flags are associated to the main AATAAA signal,
blue flags to any single letter variant of the main . More explanations are given in the
gene help file
Expression and GenBank cDNA support
Tissues where expression was observed (from 399 cDNA clones)
Origin of the cDNAs, as reported in GenBank/dbEST (tissue, stage, pathological or normal) shows that the gene is expressed in brain (seen 35 times), testis (23), lung (17), placenta (14), hypothalamus (13), uterus (13), kidney (12), breast carcinoma (11), eye (9), colon (8), prostate (8), stomach (8), 2 pooled tumors (clear cell type) (7), pancreas (7), pooled germ cell tumors (7), amygdala (6), glioblastoma (pooled) (6), bladder (5), cervix (5), hippocampus (5), liver and spleen (5), whole brain (5), breast (4), carcinoid (4), cerebellum (4), embryonic stem cell, retinoic acid andmitogen-treated hes cell line H7 (4), islets of langerhans (4), liver (4), placenta cot 25-normalized (4), thymus (4), carcinoma, cell line (3), embryonic stem cells, cell lines H1, H7, andh9 (3), glioblastoma (3), human placenta (3), leiomyosarcoma (3), lymph node (3), serous papillary carcinoma, high grade, 2pooled tumors (3), skin (3), thalamus (3), trachea (3), ascites (2), blood vessels - aorta, basilar and artery (2), chondrosarcoma (2), cochlea (2), ear (2), embryonic stem cells, dmso-treated H9 cellline (2), fetal brain (2), fetal eye (2), germinal center B cell (2), hepatocellular carcinoma (2), large cell carcinoma (2), lymphoma, follicular mixed small and largecell (2), neuroblastoma (2), placenta normal (2), pooled human melanocyte, fetal heart, andpregnant uterus (2), poorly differentiated adenocarcinoma withsignet ring cell features (2), pre-eclamptic placenta (2), retinoblastoma (2), senescent fibroblast (2), small intestine (2), sympathetic trunk (2), synovial membrane tissue from rheumatioidarthritis (2), tongue, tumor tissue (2), transitional cell papilloma, cell line (2), uterus tumor (2), 2 pooled wilms' tumors, one primary and onemetastatic to brain (once), adenocarcinoma (once), adenocarcinoma cell line (once), adenocarcinoma, cell line (once), adipose (once), adipose tissue, white (once), adrenal gland (once), anaplastic oligodendroglioma (once), anaplastic oligodendroglioma with 1p/19qloss (once), aveolar macrophage (once), bone marrow (once), bone marrow stroma (once), brain, neuroblastoma (once), caudate nucleus (once), colon tumor (once), colon tumor, RER+ (once), colonic mucosa from 3 patients with crohn'sdisease (once), colon ins (once), embryonic stem (once), embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells (once), esophageal, tumor tissue (once), fetal eyes, lens, eye anterior segment,optic nerve, retina, retina foveal and macular, RPE andchoroid (once), fibrotheoma (once), from chronic myelogenous leukemia (once), head neck (once), hypernephroma (once), left pelvis (once), left pubic bone (once), lens (once), medulloblastoma (once), melanocyte (once), melanotic melanoma (once), melanotic melanoma, high MDR (once), melanotic melanoma, high MDR (cell line) (once), metastatic chondrosarcoma (once), moderately-differentiated adenocarcinoma (once), mucoepidermoid carcinoma (once), muscle (once), myeloid cells, 18 pooled CML cases, bcr/ablrearrangement positive, includes both chronic phase andmyeloid blast crisis (once), nervous normal (once), normal endometrium, mid-secretory phase,cycle day 23 (once), normal nasopharynx (once), optic nerve (once), ovary (once), parathyroid gland (once), parathyroid tumor (once), placenta, choriocarcinoma (once), pooled-glandular (once), pooled-skin (once), primary lung cystic fibrosis epithelialcells (once), primary lung epithelial cells (once), purified pancreatic islet (once), rhabdomyosarcoma (once), rpe/choroid (once), spleen (once), squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) (once), t-lymphocytes (once), two pooled squamous cell carcinomas (once), umbilical cord (once), well-differentiated endometrialadenocarcinoma, 7 pooled tumors (once), whole blood (once).
399 cDNA clones support the 15 variants of gene HNRPLL
?
This table helps analyze the pattern of expression of the gene, the tissue, cell type or disease state specificity of the alternative variants and to select cDNA clones suitable for your experiments.
cDNA accession Links to the sequence |
Tissue
most 5' clones in red |
Match mRNA |
From bp to bp in mRNA |
From bp to bp in accs. |
Clone encodes complete protein (with AA variation) |
Features |
Anomalies detected by AceView |
Accession match over (% length) |
Base differences relative to genome (% identity) |
BF438351 | Prostate | HNRPLL.a | 1 to 605 | 605 to 1 | | tiling clone, | | 605/605 (100 %) | 0 diff (100 %id) |
AI799861 | Prostate | HNRPLL.a | 75 to 565 | 494 to 4 | | | | 491/494 (99 %) | 0 diff (100 %id) |
AI745529 | Prostate | HNRPLL.a | 102 to 605 | 504 to 1 | | | | 504/504 (100 %) | 0 diff (100 %id) |
AW149526 | brain, medulloblastoma | HNRPLL.a | 109 to 605 | 498 to 1 | | | | 498/498 (100 %) | 3 diff (99.4 %id) |
AI673606 | colon, colonic mucosa from 3 patients with Crohn'sdisease | HNRPLL.a | 159 to 605 | 447 to 1 | | | | 447/447 (100 %) | 3 diff (99.4 %id) |
BF732180 | fibrotheoma, ovary | HNRPLL.a | 229 to 595 | 367 to 1 | | | | 367/367 (100 %) | 0 diff (100 %id) |
NM_138394.3 | | HNRPLL.a | 405 to 3439 | 1 to 3035 | exact | RefSeq, AAA | | 3035/3035 (100 %) | 0 diff (100 %id) |
DA940705 | Spleen | HNRPLL.a | 406 to 678 | 2 to 275 | | capped | | 274/274 (100 %) | 1 diff (99.7 %id) |
DB127860 | thymus | HNRPLL.a | 408 to 941 | 2 to 535 | | capped | | 534/534 (100 %) | 1 diff (99.9 %id) |
DB205879 | trachea | HNRPLL.a | 409 to 982 | 2 to 576 | | capped | | 575/575 (100 %) | 4 diff (99.4 %id) |
BF979485 | testis | HNRPLL.a | 469 to 1128 | 1 to 664 | | | | 664/1053 (63 %) | 26 diff (97.6 %id) |
DB498029 | hypothalamus | HNRPLL.a | 479 to 981 | 1 to 504 | | | | 504/504 (100 %) | 1 diff (99.9 %id) |
DA006067 | | HNRPLL.a | 514 to 918 | 2 to 406 | | capped | | 405/405 (100 %) | 0 diff (100 %id) |
DA083256 | cerebellum | HNRPLL.a | 514 to 852 | 2 to 340 | | capped | | 339/339 (100 %) | 0 diff (100 %id) |
DA554314 | | HNRPLL.a | 514 to 1095 | 2 to 583 | | capped | | 582/582 (100 %) | 0 diff (100 %id) |
DA666204 | | HNRPLL.a | 514 to 1044 | 2 to 532 | | capped | | 531/531 (100 %) | 0 diff (100 %id) |
CB991958 | placenta, pre-eclamptic placenta | HNRPLL.a | 515 to 1302 | 24 to 815 | | | | 792/816 (97 %) | 15 diff (98.2 %id) |
CB961547 | placenta, pre-eclamptic placenta | HNRPLL.a | 515 to 1248 | 24 to 761 | | | | 738/791 (93 %) | 12 diff (98.5 %id) |
DA910362 | | HNRPLL.a | 516 to 886 | 2 to 372 | | capped | | 371/371 (100 %) | 4 diff (99.0 %id) |
DB119748 | thymus | HNRPLL.a | 517 to 1088 | 2 to 573 | | capped | | 572/572 (100 %) | 0 diff (100 %id) |
DA009545 | adrenal gland | HNRPLL.a | 520 to 1092 | 2 to 574 | | capped | | 573/573 (100 %) | 0 diff (100 %id) |
DA305080 | hippocampus | HNRPLL.a | 520 to 886 | 2 to 368 | | capped | | 367/367 (100 %) | 0 diff (100 %id) |
DA375899 | thalamus | HNRPLL.a | 520 to 1047 | 2 to 529 | | capped | | 528/528 (100 %) | 0 diff (100 %id) |
DA449340 | tongue, tumor tissue | HNRPLL.a | 520 to 920 | 2 to 402 | | capped | | 401/401 (100 %) | 0 diff (100 %id) |
DA529468 | brain | HNRPLL.a | 520 to 1122 | 2 to 604 | | capped | | 603/604 (99 %) | 0 diff (100 %id) |
DA612485 | | HNRPLL.a | 520 to 1083 | 2 to 565 | | capped | | 564/564 (100 %) | 0 diff (100 %id) |
DA685037 | | HNRPLL.a | 520 to 792 | 2 to 274 | | capped | | 273/273 (100 %) | 0 diff (100 %id) |
DA779031 | brain | HNRPLL.a | 520 to 963 | 2 to 445 | | capped | | 444/444 (100 %) | 0 diff (100 %id) |
DA808933 | brain | HNRPLL.a | 520 to 1087 | 2 to 572 | | capped | | 571/571 (100 %) | 2 diff (99.7 %id) |
DA814506 | | HNRPLL.a | 520 to 1075 | 2 to 557 | | capped | | 556/556 (100 %) | 1 diff (99.9 %id) |
DB083395 | testis | HNRPLL.a | 520 to 1070 | 2 to 552 | | capped | | 551/551 (100 %) | 0 diff (100 %id) |
DA160013 | amygdala | HNRPLL.a | 521 to 804 | 2 to 285 | | capped | | 284/284 (100 %) | 0 diff (100 %id) |
DA906750 | | HNRPLL.a | 521 to 772 | 2 to 253 | | capped | | 252/252 (100 %) | 0 diff (100 %id) |
DB155406 | thymus | HNRPLL.a | 521 to 1093 | 2 to 575 | | capped | | 574/574 (100 %) | 1 diff (99.9 %id) |
DA604293 | | HNRPLL.a | 522 to 916 | 2 to 397 | | capped | | 396/396 (100 %) | 1 diff (99.8 %id) |
DR002586 | fetal brain | HNRPLL.a | 525 to 1241 | 7 to 722 | | | | 716/722 (99 %) | 9 diff (98.8 %id) |
BI545217 | brain, hippocampus | HNRPLL.a | 532 to 1298 | 1 to 780 | | | | 779/781 (99 %) | 46 diff (94.2 %id) |
DN991954 | brain, whole brain | HNRPLL.a | 535 to 1160 | 1 to 627 | | | | 627/627 (100 %) | 4 diff (99.4 %id) |
DB096958 | testis | HNRPLL.a | 536 to 931 | 2 to 397 | | capped | | 396/396 (100 %) | 1 diff (99.8 %id) |
TI_44165293 | | HNRPLL.a | 537 to 1298 | 130 to 904 | | | | 774/905 (85 %) | 36 diff (96.1 %id) |
AK291462 | brain | HNRPLL.a | 540 to 2796 | 1 to 2258 | exact | tiling clone, | | 2258/2258 (100 %) | 1 diff (100.0 %id) |
CF594103 | Human Placenta, placenta | HNRPLL.a | 540 to 1338 | 28 to 843 | | | | 816/976 (83 %) | 57 diff (94.2 %id) |
DA807438 | brain | HNRPLL.a | 541 to 1054 | 2 to 515 | | capped | | 514/514 (100 %) | 0 diff (100 %id) |
DA752019 | | HNRPLL.a | 545 to 1121 | 2 to 578 | | capped | | 577/577 (100 %) | 2 diff (99.7 %id) |
DA693457 | | HNRPLL.a | 546 to 842 | 2 to 298 | | capped | | 297/297 (100 %) | 0 diff (100 %id) |
BC017480 | Brain, neuroblastoma | HNRPLL.a | 559 to 2590 | 1 to 2032 | exact | tiling clone, available from MGC, AAA | | 2032/2032 (100 %) | 0 diff (100 %id) |
CD109929 | Human Placenta, placenta | HNRPLL.a | 560 to 1292 | 21 to 768 | | | | 748/801 (93 %) | 36 diff (95.6 %id) |
CD109633 | Human Placenta, placenta | HNRPLL.a | 571 to 1319 | 27 to 782 | | | | 756/786 (96 %) | 16 diff (98.0 %id) |
DA159152 | amygdala | HNRPLL.a | 573 to 924 | 2 to 353 | | capped | | 352/352 (100 %) | 3 diff (99.2 %id) |
DA161162 | amygdala | HNRPLL.a | 573 to 1132 | 2 to 564 | | capped | | 563/563 (100 %) | 4 diff (99.3 %id) |
DA965489 | stomach | HNRPLL.a | 573 to 1129 | 2 to 558 | | capped | | 557/557 (100 %) | 0 diff (100 %id) |
DB034830 | testis | HNRPLL.a | 574 to 1089 | 2 to 520 | | capped | | 519/519 (100 %) | 4 diff (99.3 %id) |
DA917684 | small intestine | HNRPLL.a | 588 to 1150 | 2 to 565 | | capped | | 564/564 (100 %) | 1 diff (99.9 %id) |
AI475099 | anaplastic oligodendroglioma, brain | HNRPLL.a | 598 to 809 | 1 to 212 | | | Submitted on the opposite strand | 212/212 (100 %) | 0 diff (100 %id) |
BY799730 | eye | HNRPLL.a | 606 to 778 | 173 to 1 | | | Submitted on the opposite strand | 173/173 (100 %) | 0 diff (100 %id) |
H95141 | placenta | HNRPLL.a | 645 to 981 | 1 to 339 | | | Submitted on the opposite strand | 339/344 (98 %) | 18 diff (94.8 %id) |
BG717030 | testis | HNRPLL.a | 759 to 1507 | 1 to 750 | | | | 750/750 (100 %) | 4 diff (99.5 %id) |
BI912780 | brain | HNRPLL.a | 792 to 1330 | 1 to 537 | | | | 537/537 (100 %) | 2 diff (99.7 %id) |
TI_57238247 | | HNRPLL.a | 792 to 1330 | 31 to 567 | | | | 537/567 (94 %) | 6 diff (99.0 %id) |
BE260817 | brain, neuroblastoma | HNRPLL.a | 796 to 1247 | 239 to 696 | | | | 657/740 (88 %) | 62 diff (91.7 %id) |
BX378795 | Placenta Cot 25-normalized | HNRPLL.a | 797 to 1620 | 1 to 828 | | | | 422/828 (50 %) | 16 diff (98.1 %id) |
TI_1948137054 | | HNRPLL.a | 814 to 1456 | 130 to 770 | | | | 641/1334 (48 %) | 28 diff (98.0 %id) |
TI_1948137055 | | HNRPLL.a | 814 to 1619 | 124 to 931 | | | | 808/1286 (62 %) | 32 diff (97.6 %id) |
TI_1948137741 | | HNRPLL.a | 814 to 1436 | 128 to 751 | | | | 624/1406 (44 %) | 12 diff (99.2 %id) |
TI_1948137742 | | HNRPLL.a | 814 to 1548 | 126 to 862 | | | | 737/1348 (54 %) | 19 diff (98.6 %id) |
TI_1948138090 | | HNRPLL.a | 814 to 1535 | 126 to 852 | | | | 727/1419 (51 %) | 22 diff (98.5 %id) |
TI_1948138091 | | HNRPLL.a | 814 to 1619 | 124 to 929 | | | | 806/1312 (61 %) | 18 diff (98.7 %id) |
CV028121 | mixed | HNRPLL.a | 815 to 1395 | 1 to 582 | | | | 582/585 (99 %) | 1 diff (99.9 %id) |
TI_1948137392 | | HNRPLL.a | 815 to 1456 | 127 to 768 | | | | 642/1385 (46 %) | 24 diff (98.3 %id) |
TI_1948137393 | | HNRPLL.a | 815 to 1611 | 126 to 929 | | | | 804/1315 (61 %) | 22 diff (98.4 %id) |
DA718116 | | HNRPLL.a | 816 to 1335 | 2 to 522 | | capped | | 521/521 (100 %) | 2 diff (99.7 %id) |
DA928457 | small intestine | HNRPLL.a | 816 to 1380 | 2 to 568 | | capped | | 567/567 (100 %) | 5 diff (99.2 %id) |
BF980324 | testis | HNRPLL.a | 1834 to 2534 | 702 to 1 | | | | 702/702 (100 %) | 6 diff (99.2 %id) |
NM_001142650.1 | | HNRPLL.b | 1 to 2778 | 2 to 2779 | exact | RefSeq, AAA | | 2779/2779 (100 %) | 0 diff (100 %id) |
DB461823 | testis | HNRPLL.b | 1 to 479 | 1 to 479 | | tiling clone, | | 479/479 (100 %) | 0 diff (100 %id) |
DB057133 | testis | HNRPLL.b | 1 to 523 | 2 to 525 | | capped | | 524/524 (100 %) | 3 diff (99.5 %id) |
DA524129 | brain | HNRPLL.b | 2 to 560 | 2 to 561 | | capped | | 560/560 (100 %) | 1 diff (99.9 %id) |
DB041906 | testis | HNRPLL.b | 2 to 585 | 2 to 593 | | capped | | 592/592 (100 %) | 9 diff (98.5 %id) |
BG707070 | brain, hypothalamus | HNRPLL.b | 5 to 697 | 1 to 720 | | | | 720/848 (84 %) | 39 diff (95.5 %id) |
BI603042 | brain, hypothalamus | HNRPLL.b | 5 to 707 | 1 to 704 | | | | 704/775 (90 %) | 18 diff (97.7 %id) |
BI598199 | brain, hypothalamus | HNRPLL.b | 5 to 842 | 1 to 849 | | | | 849/854 (99 %) | 44 diff (94.9 %id) |
DB046890 | testis | HNRPLL.b | 6 to 558 | 2 to 555 | | capped | | 554/554 (100 %) | 2 diff (99.7 %id) |
AK292259 | testis | HNRPLL.b | 7 to 1845 | 1 to 1839 | H452R | tiling clone, | | 1839/1839 (100 %) | 1 diff (100.0 %id) |
DB038349 | testis | HNRPLL.b | 7 to 575 | 2 to 570 | | capped | | 569/569 (100 %) | 0 diff (100 %id) |
DB026276 | testis | HNRPLL.b | 8 to 570 | 2 to 564 | | capped | | 563/563 (100 %) | 0 diff (100 %id) |
TI_45215795 | | HNRPLL.b | 10 to 707 | 90 to 788 | | | | 699/859 (81 %) | 20 diff (97.7 %id) |
TI_45216056 | | HNRPLL.b | 10 to 754 | 86 to 840 | | | | 755/934 (80 %) | 25 diff (97.4 %id) |
DB472176 | hippocampus | HNRPLL.b | 11 to 502 | 1 to 492 | | | | 492/492 (100 %) | 7 diff (98.6 %id) |
DA273541 | caudate nucleus | HNRPLL.b | 13 to 563 | 2 to 552 | | capped | | 551/551 (100 %) | 0 diff (100 %id) |
BI559781 | testis | HNRPLL.b | 21 to 761 | 1 to 741 | | | | 741/743 (99 %) | 10 diff (98.7 %id) |
DB092056 | testis | HNRPLL.b | 24 to 564 | 2 to 542 | | capped | | 541/541 (100 %) | 0 diff (100 %id) |
TI_44348041 | | HNRPLL.b | 25 to 761 | 125 to 861 | | | | 737/863 (85 %) | 12 diff (98.7 %id) |
DB452427 | testis | HNRPLL.b | 33 to 518 | 1 to 486 | | | | 486/486 (100 %) | 0 diff (100 %id) |
DB458504 | testis | HNRPLL.b | 43 to 519 | 1 to 477 | | | | 477/477 (100 %) | 1 diff (99.8 %id) |
DB129494 | thymus | HNRPLL.b | 72 to 610 | 2 to 540 | | capped | | 539/539 (100 %) | 5 diff (99.1 %id) |
DB012017 | esophageal, tumor tissue | HNRPLL.b | 79 to 645 | 2 to 568 | | capped | | 567/567 (100 %) | 0 diff (100 %id) |
DA434359 | tongue, tumor tissue | HNRPLL.b | 82 to 578 | 2 to 499 | | capped | | 498/498 (100 %) | 1 diff (99.8 %id) |
AK000155 | colon | HNRPLL.b | 96 to 2455 | 1 to 2360 | G329S | tiling clone, available from FLJ, AAA | | 2360/2360 (100 %) | 1 diff (100.0 %id) |
BP221245 | colon | HNRPLL.b | 96 to 664 | 1 to 569 | | | | 569/569 (100 %) | 1 diff (99.9 %id) |
DA682948 | | HNRPLL.b | 109 to 618 | 2 to 511 | | capped | | 510/510 (100 %) | 0 diff (100 %id) |
DA701417 | | HNRPLL.b | 109 to 616 | 2 to 510 | | capped | | 509/509 (100 %) | 1 diff (99.9 %id) |
DA708242 | | HNRPLL.b | 109 to 678 | 2 to 576 | | capped | | 575/575 (100 %) | 5 diff (99.2 %id) |
DA747635 | | HNRPLL.b | 115 to 689 | 2 to 576 | | capped | | 575/575 (100 %) | 0 diff (100 %id) |
DA813348 | | HNRPLL.b | 115 to 660 | 2 to 547 | | capped | | 546/546 (100 %) | 1 diff (99.9 %id) |
DA989146 | synovial membrane tissue from rheumatioidarthritis | HNRPLL.b | 115 to 677 | 2 to 566 | | capped | | 565/565 (100 %) | 3 diff (99.5 %id) |
DA226537 | brain | HNRPLL.b | 117 to 760 | 2 to 645 | | capped | | 644/644 (100 %) | 1 diff (99.9 %id) |
DA541984 | lung | HNRPLL.b | 117 to 692 | 2 to 577 | | capped | | 576/576 (100 %) | 0 diff (100 %id) |
CN297797 | embryonic stem cells, cell lines H1, H7, andH9 | HNRPLL.b | 127 to 695 | 7 to 576 | | | | 570/576 (98 %) | 7 diff (98.8 %id) |
BE540940 | cervix | HNRPLL.b | 128 to 706 | 1 to 584 | | | | 584/893 (65 %) | 9 diff (99.0 %id) |
CN297791 | embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 | HNRPLL.b | 134 to 878 | 1 to 745 | | | | 745/745 (100 %) | 0 diff (100 %id) |
BG767190 | melanotic melanoma, high MDR (cell line), skin | HNRPLL.b | 136 to 760 | 1 to 623 | | | | 623/643 (96 %) | 13 diff (98.0 %id) |
CX873668 | embryonic stem | HNRPLL.b | 156 to 953 | 1 to 798 | | | | 798/798 (100 %) | 0 diff (100 %id) |
TI_1948229258 | | HNRPLL.b | 162 to 882 | 123 to 844 | | | | 722/1311 (55 %) | 20 diff (98.5 %id) |
TI_1948229561 | | HNRPLL.b | 162 to 883 | 122 to 846 | | | | 725/1387 (52 %) | 31 diff (97.8 %id) |
AA204747 | | HNRPLL.b | 165 to 555 | 1 to 391 | | | | 394/391 (100 %) | 10 diff (97.5 %id) |
EL736416 | mixed | HNRPLL.b | 169 to 785 | 1 to 617 | | | | 617/625 (98 %) | 7 diff (98.9 %id) |
BX366650 | Placenta Cot 25-normalized | HNRPLL.b | 171 to 986 | 1 to 814 | | fully sequenced, | | 814/814 (100 %) | 6 diff (99.3 %id) |
TI_1948229257 | | HNRPLL.b | 179 to 350 | 144 to 315 | | | | 172/210 (81 %) | 6 diff (97.2 %id) |
DA468775 | | HNRPLL.b | 197 to 748 | 2 to 553 | | capped | | 552/552 (100 %) | 0 diff (100 %id) |
AA100850 | Pancreas | HNRPLL.b | 198 to 645 | 52 to 500 | | | | 449/500 (89 %) | 10 diff (98.0 %id) |
BG469783 | adenocarcinoma cell line, colon | HNRPLL.b | 203 to 705 | 1 to 506 | | | | 506/725 (69 %) | 10 diff (98.7 %id) |
DA991758 | synovial membrane tissue from rheumatioidarthritis | HNRPLL.b | 221 to 770 | 2 to 552 | | capped | | 551/551 (100 %) | 2 diff (99.7 %id) |
BE294299 | muscle, rhabdomyosarcoma | HNRPLL.b | 261 to 954 | 1 to 694 | | | | 694/775 (89 %) | 27 diff (96.6 %id) |
CT001979 | T-Lymphocytes | HNRPLL.b | 268 to 946 | 1 to 682 | | | | 682/690 (98 %) | 9 diff (98.7 %id) |
CN297794 | embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells | HNRPLL.b | 313 to 778 | 1 to 466 | | | | 466/466 (100 %) | 3 diff (99.4 %id) |
BM718873 | eye, fetal eye | HNRPLL.b | 314 to 1026 | 1 to 711 | | | | 711/711 (100 %) | 2 diff (99.8 %id) |
BG205026 | | HNRPLL.b | 338 to 1149 | 1 to 814 | | | | 814/814 (100 %) | 12 diff (98.6 %id) |
BX418659 | brain, fetal brain | HNRPLL.b | 343 to 1082 | 3 to 742 | | | | 742/742 (100 %) | 1 diff (99.9 %id) |
BI090008 | cervix | HNRPLL.b | 380 to 958 | 1 to 583 | | | | 583/730 (79 %) | 11 diff (98.5 %id) |
DB277596 | uterus | HNRPLL.b | 391 to 934 | 2 to 545 | | capped | | 544/544 (100 %) | 0 diff (100 %id) |
CB216871 | normal endometrium, mid-secretory phase,cycle day 23, uterus | HNRPLL.b | 393 to 1036 | 1 to 644 | | | | 644/644 (100 %) | 0 diff (100 %id) |
AA429977 | | HNRPLL.b | 416 to 910 | 1 to 496 | | | | 496/496 (100 %) | 1 diff (99.8 %id) |
AA442550 | | HNRPLL.b | 418 to 999 | 1 to 581 | | | | 581/581 (100 %) | 1 diff (99.9 %id) |
BF687975 | brain, glioblastoma | HNRPLL.b | 459 to 1028 | 1 to 570 | | | | 570/809 (70 %) | 16 diff (98.1 %id) |
BP239815 | Liver | HNRPLL.b | 460 to 1072 | 1 to 613 | | | | 613/614 (99 %) | 7 diff (98.9 %id) |
BF691388 | melanotic melanoma, high MDR, skin | HNRPLL.b | 470 to 1190 | 1 to 727 | | | | 727/757 (96 %) | 20 diff (97.4 %id) |
CB108218 | Liver | HNRPLL.b | 474 to 941 | 1 to 468 | | | | 468/468 (100 %) | 1 diff (99.8 %id) |
BI091760 | cervix | HNRPLL.b | 477 to 1290 | 1 to 820 | | | | 820/820 (100 %) | 18 diff (97.9 %id) |
DA710809 | | HNRPLL.b | 507 to 1062 | 2 to 557 | | capped | | 556/556 (100 %) | 1 diff (99.9 %id) |
AA079181 | | HNRPLL.b | 508 to 787 | 1 to 281 | | fully sequenced, | | 281/281 (100 %) | 2 diff (99.3 %id) |
BE784427 | large cell carcinoma, lung | HNRPLL.b | 533 to 1245 | 1 to 713 | | | | 713/950 (75 %) | 13 diff (98.7 %id) |
AA600090 | bone marrow stroma | HNRPLL.b | 535 to 1056 | 522 to 1 | | | | 522/522 (100 %) | 0 diff (100 %id) |
BU182172 | eye, retinoblastoma | HNRPLL.b | 535 to 1466 | 7 to 940 | | | | 934/940 (99 %) | 15 diff (98.5 %id) |
CN297789 | embryonic stem cells, DMSO-treated H9 cellline | HNRPLL.b | 537 to 897 | 1 to 361 | | | | 361/361 (100 %) | 0 diff (100 %id) |
DA551642 | | HNRPLL.b | 543 to 1056 | 2 to 515 | | capped | | 514/514 (100 %) | 0 diff (100 %id) |
CD356144 | Blood vessels - aorta, basilar and artery | HNRPLL.b | 577 to 1246 | 1 to 676 | | | | 676/748 (90 %) | 10 diff (98.7 %id) |
R55883 | whole brain | HNRPLL.b | 578 to 1028 | 1 to 455 | | | | 455/505 (90 %) | 10 diff (98.1 %id) |
CN297792 | embryonic stem cells, cell lines H1, H7, andH9 | HNRPLL.b | 584 to 1272 | 1 to 690 | | | | 690/690 (100 %) | 4 diff (99.5 %id) |
BG494510 | lung, mucoepidermoid carcinoma | HNRPLL.b | 608 to 1235 | 1 to 629 | | | | 629/630 (99 %) | 15 diff (97.7 %id) |
DA184963 | amygdala | HNRPLL.b | 670 to 1202 | 2 to 535 | | capped | | 534/534 (100 %) | 1 diff (99.9 %id) |
CN297793 | embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 | HNRPLL.b | 682 to 948 | 1 to 267 | | | | 267/267 (100 %) | 1 diff (99.7 %id) |
DA237052 | brain | HNRPLL.b | 694 to 1269 | 2 to 577 | | capped | | 576/576 (100 %) | 0 diff (100 %id) |
DA803832 | brain | HNRPLL.b | 707 to 1249 | 2 to 544 | | capped | | 543/546 (99 %) | 2 diff (99.7 %id) |
DA803881 | brain | HNRPLL.b | 707 to 1253 | 2 to 549 | | capped | | 548/549 (99 %) | 5 diff (99.1 %id) |
CB267648 | adipose | HNRPLL.b | 749 to 1267 | 1 to 520 | | | | 520/520 (100 %) | 1 diff (99.9 %id) |
AA079182 | | HNRPLL.b | 755 to 1057 | 307 to 1 | | fully sequenced, | | 307/307 (100 %) | 2 diff (99.4 %id) |
DA731774 | | HNRPLL.b | 790 to 1563 | 2 to 781 | | capped | | 780/837 (93 %) | 14 diff (98.4 %id) |
BQ277226 | mixed (pool of 40 RNAs) | HNRPLL.b | 842 to 1554 | 1 to 717 | | | | 717/937 (76 %) | 18 diff (98.1 %id) |
CK820297 | Islets of Langerhans, Pancreas | HNRPLL.b | 843 to 1437 | 1 to 595 | | | | 595/595 (100 %) | 0 diff (100 %id) |
BM142388 | Islets of Langerhans, Pancreas | HNRPLL.b | 859 to 1426 | 1 to 568 | | | | 568/568 (100 %) | 0 diff (100 %id) |
FN114165 | breast carcinoma | HNRPLL.b | 871 to 978 | 109 to 1 | | | Submitted on the opposite strand | 109/109 (100 %) | 1 diff (99.1 %id) |
TI_1948138093 | | HNRPLL.b | 883 to 1781 | 1036 to 131 | | | | 906/1391 (65 %) | 16 diff (98.9 %id) |
TI_1948138092 | | HNRPLL.b | 885 to 1781 | 1023 to 126 | | | | 898/1083 (82 %) | 14 diff (98.8 %id) |
BE937224 | stomach | HNRPLL.b | 894 to 1554 | 9 to 669 | | | | 661/670 (98 %) | 18 diff (97.4 %id) |
TI_1948137056 | | HNRPLL.b | 894 to 1781 | 1021 to 128 | | | | 894/1117 (80 %) | 15 diff (98.7 %id) |
TI_1948137394 | | HNRPLL.b | 894 to 1781 | 1027 to 126 | | | | 900/1119 (80 %) | 18 diff (98.4 %id) |
TI_1948137743 | | HNRPLL.b | 894 to 1785 | 1019 to 119 | | | | 901/1116 (80 %) | 20 diff (98.3 %id) |
BF208028 | bladder, carcinoma, cell line | HNRPLL.b | 912 to 1365 | 1 to 468 | | | | 468/538 (86 %) | 26 diff (95.2 %id) |
BE865855 | bladder, carcinoma, cell line | HNRPLL.b | 914 to 1571 | 1 to 645 | | | | 647/845 (76 %) | 23 diff (97.3 %id) |
TI_57220402 | | HNRPLL.b | 923 to 1789 | 25 to 894 | | | | 870/894 (97 %) | 30 diff (96.7 %id) |
BX366649 | Placenta Cot 25-normalized | HNRPLL.b | 925 to 1861 | 930 to 1 | | fully sequenced, | | 930/930 (100 %) | 13 diff (98.7 %id) |
BI757445 | brain | HNRPLL.b | 927 to 1789 | 1 to 865 | | | | 865/865 (100 %) | 25 diff (97.2 %id) |
BE072770 | breast | HNRPLL.b | 950 to 1417 | 1 to 463 | | | | 463/463 (100 %) | 18 diff (96.2 %id) |
TI_1948137744 | | HNRPLL.b | 953 to 1785 | 969 to 130 | | | | 796/1383 (57 %) | 35 diff (97.5 %id) |
BE568417 | bladder, carcinoma, cell line | HNRPLL.b | 956 to 1489 | 1 to 548 | | | | 550/788 (69 %) | 48 diff (94.0 %id) |
CN297790 | embryonic stem cells, cell lines H1, H7, andH9 | HNRPLL.b | 959 to 1489 | 1 to 531 | | | | 531/531 (100 %) | 1 diff (99.9 %id) |
AW374054 | breast | HNRPLL.b | 965 to 1580 | 1 to 615 | | | | 615/624 (98 %) | 10 diff (98.4 %id) |
AW374040 | breast | HNRPLL.b | 966 to 1553 | 1 to 587 | | | | 587/618 (94 %) | 16 diff (97.5 %id) |
BU153637 | eye, retinoblastoma | HNRPLL.b | 976 to 1887 | 1 to 918 | | | | 918/919 (99 %) | 16 diff (98.3 %id) |
TI_1948137395 | | HNRPLL.b | 977 to 1781 | 928 to 129 | | | | 800/1347 (59 %) | 15 diff (98.9 %id) |
BF094799 | uterus_tumor | HNRPLL.b | 983 to 1405 | 1 to 423 | | | | 423/423 (100 %) | 7 diff (98.4 %id) |
BF094741 | uterus_tumor | HNRPLL.b | 984 to 1405 | 1 to 422 | | | | 422/422 (100 %) | 2 diff (99.6 %id) |
CB128730 | Liver | HNRPLL.b | 988 to 1605 | 1 to 618 | | | | 618/618 (100 %) | 0 diff (100 %id) |
CA949944 | Pancreas, Purified pancreatic islet | HNRPLL.b | 997 to 1629 | 1 to 633 | | | | 633/633 (100 %) | 1 diff (99.9 %id) |
FN129624 | breast carcinoma | HNRPLL.b | 1027 to 1127 | 97 to 1 | | | Submitted on the opposite strand | 97/98 (98 %) | 4 diff (96.0 %id) |
TI_1948137057 | | HNRPLL.b | 1027 to 1781 | 878 to 125 | | | | 754/1224 (61 %) | 31 diff (97.5 %id) |
DA169420 | amygdala | HNRPLL.b | 1030 to 1602 | 2 to 574 | | capped | | 573/573 (100 %) | 0 diff (100 %id) |
BQ722427 | sympathetic trunk | HNRPLL.b | 1065 to 1927 | 1 to 872 | | | | 872/874 (99 %) | 15 diff (98.3 %id) |
BE868723 | adenocarcinoma, colon | HNRPLL.b | 1092 to 1781 | 1 to 684 | | | | 686/685 (100 %) | 10 diff (98.6 %id) |
BG708970 | brain, hypothalamus | HNRPLL.b | 1134 to 1860 | 1 to 725 | | | | 725/728 (99 %) | 11 diff (98.5 %id) |
DB489397 | hypothalamus | HNRPLL.b | 1139 to 1616 | 1 to 479 | | | | 479/479 (100 %) | 12 diff (97.5 %id) |
DA386953 | thalamus | HNRPLL.b | 1151 to 1726 | 2 to 578 | | capped | | 577/577 (100 %) | 1 diff (99.9 %id) |
AI559701 | uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors | HNRPLL.b | 1153 to 1931 | 776 to 1 | | | | 776/776 (100 %) | 23 diff (97.1 %id) |
EB361037 | eye, lens | HNRPLL.b | 1154 to 1844 | 700 to 11 | | AAA | Possibly primed on the genome, locally A rich (9/9 A in genome downstream of last aligned base) | 690/690 (100 %) | 5 diff (99.3 %id) |
TI_149291898 | | HNRPLL.b | 1163 to 1865 | 788 to 88 | | AAA | | 701/702 (99 %) | 4 diff (99.5 %id) |
TI_154115771 | | HNRPLL.b | 1165 to 1929 | 878 to 125 | | AAA | | 754/912 (82 %) | 30 diff (96.8 %id) |
N28387 | melanocyte | HNRPLL.b | 1167 to 1507 | 348 to 1 | | | Submitted on the opposite strand | 348/359 (96 %) | 7 diff (98.1 %id) |
BU682283 | lung | HNRPLL.b | 1185 to 1865 | 699 to 19 | | AAA | | 681/681 (100 %) | 0 diff (100 %id) |
AI916721 | pooled germ cell tumors | HNRPLL.b | 1189 to 1866 | 684 to 9 | | | | 676/684 (98 %) | 7 diff (99.0 %id) |
BF239459 | bone marrow, from chronic myelogenous leukemia | HNRPLL.b | 1216 to 1685 | 1 to 471 | | | | 471/471 (100 %) | 6 diff (98.8 %id) |
AW813042 | stomach | HNRPLL.b | 1221 to 1847 | 1 to 627 | | | | 627/627 (100 %) | 2 diff (99.7 %id) |
BU928364 | brain, glioblastoma | HNRPLL.b | 1221 to 1864 | 1 to 651 | | | | 651/838 (77 %) | 9 diff (99.0 %id) |
AA320583 | adipose tissue, white | HNRPLL.b | 1237 to 1599 | 1 to 366 | | | | 366/366 (100 %) | 9 diff (97.6 %id) |
FN112937 | breast carcinoma | HNRPLL.b | 1238 to 1316 | 1 to 78 | | | | 78/78 (100 %) | 6 diff (92.4 %id) |
BM680747 | eye, fetal eye | HNRPLL.b | 1242 to 1929 | 706 to 19 | | AAA | | 688/688 (100 %) | 0 diff (100 %id) |
BU852105 | testis | HNRPLL.b | 1243 to 1932 | 1 to 692 | | | | 692/827 (83 %) | 9 diff (99.0 %id) |
TI_158433151 | | HNRPLL.b | 1247 to 1946 | 803 to 102 | | AAA | | 702/836 (83 %) | 6 diff (99.3 %id) |
BE018776 | cervix | HNRPLL.b | 1249 to 1600 | 1 to 352 | | fully sequenced, | | 352/352 (100 %) | 0 diff (100 %id) |
AI884490 | serous papillary carcinoma, high grade, 2pooled tumors, uterus | HNRPLL.b | 1250 to 1859 | 611 to 1 | | | | 611/611 (100 %) | 2 diff (99.7 %id) |
AV727556 | hypothalamus | HNRPLL.b | 1322 to 1957 | 1 to 637 | | | | 637/643 (99 %) | 15 diff (97.7 %id) |
CD102520 | Pooled-Skin | HNRPLL.b | 1345 to 2070 | 1 to 734 | | | | 734/734 (100 %) | 16 diff (97.9 %id) |
BG291991 | bladder, transitional cell papilloma, cell line | HNRPLL.b | 1358 to 1946 | 1 to 588 | | AAA | | 588/588 (100 %) | 2 diff (99.7 %id) |
CK820296 | Islets of Langerhans, Pancreas | HNRPLL.b | 1358 to 1947 | 590 to 1 | | | | 590/590 (100 %) | 0 diff (100 %id) |
BP373350 | umbilical cord | HNRPLL.b | 1366 to 1864 | 1 to 499 | | | | 499/505 (98 %) | 7 diff (98.7 %id) |
AW274373 | pooled | HNRPLL.b | 1367 to 1926 | 570 to 11 | | AAA | | 560/579 (96 %) | 4 diff (99.4 %id) |
BM142547 | Islets of Langerhans, Pancreas | HNRPLL.b | 1369 to 1947 | 579 to 1 | | | | 579/579 (100 %) | 0 diff (100 %id) |
AW582008 | stomach | HNRPLL.b | 1371 to 1914 | 545 to 2 | | | | 544/545 (99 %) | 7 diff (98.8 %id) |
BF196666 | brain, glioblastoma (pooled) | HNRPLL.b | 1387 to 1929 | 543 to 1 | | | | 543/543 (100 %) | 2 diff (99.7 %id) |
AI286178 | pooled | HNRPLL.b | 1390 to 1932 | 549 to 7 | | | | 543/549 (98 %) | 5 diff (99.1 %id) |
FN060014 | breast carcinoma | HNRPLL.b | 1404 to 1498 | 1 to 95 | | | | 95/95 (100 %) | 0 diff (100 %id) |
BE858611 | brain, glioblastoma (pooled) | HNRPLL.b | 1405 to 1929 | 525 to 1 | | | | 525/525 (100 %) | 0 diff (100 %id) |
AA906310 | pooled | HNRPLL.b | 1415 to 1870 | 454 to 1 | | | | 454/454 (100 %) | 23 diff (95.0 %id) |
BG572616 | placenta | HNRPLL.b | 1416 to 2271 | 1 to 856 | | | | 856/856 (100 %) | 13 diff (98.5 %id) |
AI079210 | brain, glioblastoma (pooled) | HNRPLL.b | 1417 to 1931 | 514 to 1 | | | | 514/514 (100 %) | 6 diff (98.9 %id) |
DB524006 | testis | HNRPLL.b | 1422 to 1863 | 1 to 442 | | | Submitted on the opposite strand | 442/442 (100 %) | 1 diff (99.8 %id) |
CN297796 | embryonic stem cells, DMSO-treated H9 cellline | HNRPLL.b | 1426 to 1929 | 514 to 11 | | AAA | Submitted on the opposite strand | 504/504 (100 %) | 3 diff (99.5 %id) |
AI159865 | brain, glioblastoma (pooled) | HNRPLL.b | 1429 to 1929 | 501 to 1 | | | | 501/501 (100 %) | 0 diff (100 %id) |
CF528697 | placenta | HNRPLL.b | 1434 to 1946 | 530 to 18 | | AAA | | 513/513 (100 %) | 0 diff (100 %id) |
CA449431 | Chondrosarcoma, Left Pelvis | HNRPLL.b | 1435 to 1929 | 513 to 19 | | AAA | | 495/495 (100 %) | 18 diff (96.4 %id) |
AW264931 | lung, two pooled squamous cell carcinomas | HNRPLL.b | 1441 to 1774 | 334 to 1 | | | | 334/337 (99 %) | 14 diff (95.9 %id) |
BF132400 | hypernephroma, Kidney | HNRPLL.b | 1449 to 1929 | 1 to 478 | | AAA | | 478/478 (100 %) | 10 diff (98.0 %id) |
AI127951 | uterus | HNRPLL.b | 1468 to 1946 | 492 to 14 | | AAA | | 479/479 (100 %) | 0 diff (100 %id) |
AI307220 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.b | 1471 to 1932 | 462 to 1 | | | | 462/462 (100 %) | 0 diff (100 %id) |
AI334616 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.b | 1471 to 1949 | 480 to 2 | | | | 479/480 (99 %) | 1 diff (99.8 %id) |
AA975224 | pooled germ cell tumors | HNRPLL.b | 1480 to 1949 | 469 to 1 | | | | 469/469 (100 %) | 2 diff (99.6 %id) |
AI097117 | brain, glioblastoma (pooled) | HNRPLL.b | 1480 to 1931 | 452 to 1 | | | | 452/452 (100 %) | 0 diff (100 %id) |
AI669259 | Prostate | HNRPLL.b | 1487 to 1932 | 447 to 2 | | | | 446/447 (99 %) | 0 diff (100 %id) |
AW013801 | | HNRPLL.b | 1491 to 1929 | 456 to 18 | | AAA | | 439/439 (100 %) | 3 diff (99.4 %id) |
AI167572 | mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus | HNRPLL.b | 1492 to 1926 | 444 to 11 | | AAA | | 434/434 (100 %) | 1 diff (99.8 %id) |
AI655053 | pooled germ cell tumors | HNRPLL.b | 1505 to 1949 | 445 to 1 | | | | 445/445 (100 %) | 0 diff (100 %id) |
BF059451 | pooled germ cell tumors | HNRPLL.b | 1506 to 1949 | 444 to 1 | | | | 444/444 (100 %) | 0 diff (100 %id) |
W45728 | senescent fibroblast | HNRPLL.b | 1507 to 1946 | 454 to 11 | | AAA | | 444/454 (97 %) | 8 diff (98.3 %id) |
AI968880 | pooled germ cell tumors | HNRPLL.b | 1507 to 1951 | 466 to 22 | | AAA | | 445/445 (100 %) | 3 diff (99.4 %id) |
AI308177 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.b | 1510 to 1949 | 443 to 4 | | | | 440/446 (98 %) | 0 diff (100 %id) |
AI302235 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.b | 1516 to 1949 | 434 to 1 | | | | 434/434 (100 %) | 0 diff (100 %id) |
D62127 | | HNRPLL.b | 1530 to 1755 | 10 to 234 | | | | 225/234 (96 %) | 7 diff (97.1 %id) |
BE302339 | cervix | HNRPLL.b | 1539 to 1866 | 328 to 1 | | fully sequenced, | | 328/328 (100 %) | 0 diff (100 %id) |
CB986623 | Pooled-Glandular | HNRPLL.b | 1544 to 2257 | 1 to 723 | | | | 723/892 (81 %) | 25 diff (97.2 %id) |
CR745688 | | HNRPLL.b | 1546 to 1947 | 417 to 15 | | AAA | | 403/403 (100 %) | 3 diff (99.3 %id) |
BQ010653 | placenta | HNRPLL.b | 1550 to 1946 | 414 to 18 | | AAA | | 397/397 (100 %) | 3 diff (99.3 %id) |
CN423065 | embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 | HNRPLL.b | 1551 to 1933 | 1 to 383 | | | | 383/383 (100 %) | 0 diff (100 %id) |
R49057.
matches multiple genes | whole brain | HNRPLL.b | 1568 to 1946 | 392 to 13 | | AAA | also hits gene BRD3 | 380/424 (89 %) | 3 diff (99.3 %id) |
AI887736 | serous papillary carcinoma, high grade, 2pooled tumors, uterus | HNRPLL.b | 1568 to 1929 | 389 to 28 | | AAA | | 362/432 (83 %) | 6 diff (98.7 %id) |
AA446239 | | HNRPLL.b | 1572 to 1929 | 358 to 1 | | | | 358/358 (100 %) | 2 diff (99.5 %id) |
BG284205 | adenocarcinoma, cell line, Prostate | HNRPLL.b | 1600 to 1946 | 1 to 347 | | AAA | | 347/347 (100 %) | 0 diff (100 %id) |
BM739494 | Ascites, stomach | HNRPLL.b | 1600 to 1865 | 1 to 266 | | AAA | | 266/266 (100 %) | 0 diff (100 %id) |
AI095401 | senescent fibroblast | HNRPLL.b | 1630 to 1946 | 326 to 11 | | AAA | | 316/316 (100 %) | 1 diff (99.7 %id) |
BU154725 | melanotic melanoma, skin | HNRPLL.b | 1638 to 2456 | 1 to 826 | | AAA | | 826/826 (100 %) | 13 diff (98.5 %id) |
AI915779 | pooled | HNRPLL.b | 1645 to 1948 | 304 to 1 | | | | 304/304 (100 %) | 0 diff (100 %id) |
AI638152 | pooled germ cell tumors | HNRPLL.b | 1654 to 1946 | 293 to 1 | | | | 293/293 (100 %) | 0 diff (100 %id) |
BF115601 | brain, glioblastoma (pooled) | HNRPLL.b | 1654 to 1774 | 121 to 1 | | | | 121/121 (100 %) | 1 diff (99.2 %id) |
TI_151733884 | | HNRPLL.b | 1665 to 2036 | 446 to 75 | | | | 372/1039 (35 %) | 0 diff (100 %id) |
BQ189559 | eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid | HNRPLL.b | 1666 to 2036 | 1 to 371 | | | | 371/397 (93 %) | 1 diff (99.8 %id) |
EB387197 | eye, optic nerve | HNRPLL.b | 1701 to 2570 | 1 to 870 | | | | 870/870 (100 %) | 0 diff (100 %id) |
FN093964 | breast carcinoma | HNRPLL.b | 1723 to 1791 | 1 to 68 | | | | 68/69 (98 %) | 4 diff (94.3 %id) |
BG287902 | bladder, transitional cell papilloma, cell line | HNRPLL.b | 1724 to 2454 | 1 to 729 | | | | 729/744 (97 %) | 10 diff (98.7 %id) |
BM784794 | Ascites, stomach | HNRPLL.b | 1759 to 2177 | 1 to 419 | | | | 419/419 (100 %) | 1 diff (99.8 %id) |
BE551486 | pooled germ cell tumors | HNRPLL.b | 1787 to 1946 | 182 to 1 | | | | 182/182 (100 %) | 24 diff (86.9 %id) |
AA759359 | | HNRPLL.b | 1792 to 1929 | 153 to 16 | | AAA | | 138/138 (100 %) | 0 diff (100 %id) |
FN157565 | breast carcinoma | HNRPLL.b | 1862 to 1957 | 96 to 1 | | | Submitted on the opposite strand | 96/96 (100 %) | 0 diff (100 %id) |
GD146115 | | HNRPLL.b | 1874 to 1948 | 1 to 75 | | | | 75/88 (85 %) | 5 diff (94.4 %id) |
FN064909 | breast carcinoma | HNRPLL.b | 1881 to 1962 | 1 to 80 | | | | 80/82 (97 %) | 4 diff (95.2 %id) |
AW273811 | pooled | HNRPLL.b | 1882 to 2453 | 579 to 8 | | | | 572/579 (98 %) | 0 diff (100 %id) |
AI434522 | lymph node, lymphoma, follicular mixed small and largecell | HNRPLL.b | 1888 to 2239 | 352 to 1 | | | | 352/352 (100 %) | 0 diff (100 %id) |
AI765457 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.b | 1893 to 2456 | 568 to 5 | | | | 564/568 (99 %) | 0 diff (100 %id) |
C02294 | | HNRPLL.b | 1894 to 1946 | 1 to 53 | | | | 53/53 (100 %) | 0 diff (100 %id) |
CB962382 | Blood vessels - aorta, basilar and artery | HNRPLL.b | 1907 to 2454 | 610 to 60 | | AAA | Submitted on the opposite strand | 551/725 (76 %) | 20 diff (97.3 %id) |
DB251389 | uterus | HNRPLL.b | 1919 to 2390 | 2 to 473 | | capped | | 472/472 (100 %) | 0 diff (100 %id) |
AA100797 | Pancreas | HNRPLL.b | 1929 to 2256 | 361 to 33 | | | | 329/361 (91 %) | 0 diff (100 %id) |
BQ020310 | Chondrosarcoma, Left Pubic Bone | HNRPLL.b | 1938 to 2455 | 535 to 19 | | AAA | | 517/517 (100 %) | 1 diff (99.9 %id) |
AW474947 | poorly differentiated adenocarcinoma withsignet ring cell features, stomach | HNRPLL.b | 1950 to 2456 | 507 to 1 | | | | 507/507 (100 %) | 0 diff (100 %id) |
AI340095 | | HNRPLL.b | 1952 to 2456 | 507 to 3 | | | | 505/507 (99 %) | 0 diff (100 %id) |
BF588733 | colon, colon tumor, RER+ | HNRPLL.b | 1955 to 2456 | 504 to 3 | | | | 502/504 (99 %) | 0 diff (100 %id) |
AI373154 | uterus | HNRPLL.b | 1968 to 2455 | 499 to 12 | | AAA | | 488/488 (100 %) | 0 diff (100 %id) |
AW511983 | lymph node, lymphoma, follicular mixed small and largecell | HNRPLL.b | 1971 to 2455 | 485 to 1 | | | | 485/485 (100 %) | 3 diff (99.4 %id) |
TI_149286927 | | HNRPLL.b | 1986 to 2778 | 881 to 96 | | AAA | | 786/1097 (71 %) | 26 diff (97.7 %id) |
DB569124 | hypothalamus | HNRPLL.b | 1994 to 2453 | 1 to 460 | | | Submitted on the opposite strand | 460/462 (99 %) | 1 diff (99.8 %id) |
AI374839 | | HNRPLL.b | 2000 to 2461 | 464 to 3 | | | | 462/464 (99 %) | 0 diff (100 %id) |
DB574526 | hypothalamus | HNRPLL.b | 2006 to 2455 | 1 to 450 | | | Submitted on the opposite strand | 450/450 (100 %) | 0 diff (100 %id) |
AA665776 | | HNRPLL.b | 2013 to 2239 | 229 to 3 | | | | 227/229 (99 %) | 0 diff (100 %id) |
FN125337 | breast carcinoma | HNRPLL.b | 2038 to 2146 | 106 to 1 | | | Submitted on the opposite strand | 106/106 (100 %) | 5 diff (95.3 %id) |
BX641557 | | HNRPLL.b | 2063 to 2455 | 436 to 44 | | AAA | Submitted on the opposite strand | 393/393 (100 %) | 5 diff (98.8 %id) |
R55801 | whole brain | HNRPLL.b | 2084 to 2459 | 396 to 14 | | AAA | | 383/385 (99 %) | 10 diff (97.5 %id) |
AA788594 | | HNRPLL.b | 2096 to 2455 | 360 to 1 | | | | 360/360 (100 %) | 0 diff (100 %id) |
AW150549 | serous papillary carcinoma, high grade, 2pooled tumors, uterus | HNRPLL.b | 2106 to 2455 | 353 to 1 | | | | 353/353 (100 %) | 3 diff (99.2 %id) |
AI565388 | Kidney | HNRPLL.b | 2113 to 2456 | 344 to 1 | | | | 344/344 (100 %) | 0 diff (100 %id) |
CA395569 | eye, RPE/choroid | HNRPLL.b | 2120 to 2455 | 1 to 336 | | AAA | | 336/336 (100 %) | 0 diff (100 %id) |
AA772017 | parathyroid gland, parathyroid tumor | HNRPLL.b | 2134 to 2456 | 323 to 1 | | | | 323/323 (100 %) | 0 diff (100 %id) |
AA912882 | pooled | HNRPLL.b | 2136 to 2456 | 323 to 2 | | | | 322/323 (99 %) | 0 diff (100 %id) |
AW014320 | | HNRPLL.b | 2138 to 2455 | 335 to 18 | | AAA | | 318/318 (100 %) | 4 diff (98.8 %id) |
BM972334 | lung | HNRPLL.b | 2138 to 2778 | 659 to 19 | | tiling clone, AAA | | 641/641 (100 %) | 5 diff (99.3 %id) |
AW020079 | cochlea, ear | HNRPLL.b | 2143 to 2455 | 1 to 313 | | fully sequenced, AAA | | 313/313 (100 %) | 5 diff (98.5 %id) |
AW194581 | 2 pooled Wilms' tumors, one primary and onemetastatic to brain, Kidney | HNRPLL.b | 2184 to 2455 | 284 to 13 | | AAA | | 272/272 (100 %) | 2 diff (99.3 %id) |
BI491102 | cochlea, ear | HNRPLL.b | 2188 to 2455 | 290 to 23 | | fully sequenced, AAA | | 268/268 (100 %) | 1 diff (99.7 %id) |
DB571439 | hypothalamus | HNRPLL.b | 2268 to 2455 | 1 to 188 | | | Submitted on the opposite strand | 188/188 (100 %) | 4 diff (97.9 %id) |
AI123437 | mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus | HNRPLL.b | 2286 to 2778 | 509 to 17 | | AAA | | 493/493 (100 %) | 3 diff (99.4 %id) |
DB517931 | testis | HNRPLL.b | 2300 to 2455 | 1 to 156 | | | Submitted on the opposite strand | 156/156 (100 %) | 9 diff (94.3 %id) |
AI620131 | poorly differentiated adenocarcinoma withsignet ring cell features, stomach | HNRPLL.b | 2309 to 2778 | 472 to 3 | | | | 470/472 (99 %) | 0 diff (100 %id) |
DB540931 | hippocampus | HNRPLL.b | 2315 to 2777 | 1 to 463 | | | Submitted on the opposite strand | 463/463 (100 %) | 0 diff (100 %id) |
DB551743 | hippocampus | HNRPLL.b | 2315 to 2777 | 1 to 463 | | | Submitted on the opposite strand | 463/463 (100 %) | 0 diff (100 %id) |
TI_149271824 | | HNRPLL.b | 2365 to 2774 | 505 to 94 | | AAA | | 412/1012 (40 %) | 5 diff (99.6 %id) |
BU674665 | lung, Primary Lung Epithelial Cells | HNRPLL.b | 2365 to 2774 | 431 to 20 | | AAA | | 412/442 (93 %) | 5 diff (98.9 %id) |
FN160574 | breast carcinoma | HNRPLL.b | 2382 to 2453 | 69 to 1 | | | Submitted on the opposite strand | 69/72 (95 %) | 3 diff (95.9 %id) |
CR600541 | Placenta Cot 25-normalized | HNRPLL.c | 1 to 1691 | 1 to 1691 | exact | tiling clone, | | 1691/1691 (100 %) | 0 diff (100 %id) |
R34508.
matches multiple genes | whole brain | HNRPLL.c | 312 to 663 | 1 to 358 | | | also hits gene BRD3 | 358/360 (99 %) | 8 diff (97.8 %id) |
BQ428471 | leiomyosarcoma, uterus | HNRPLL.c | 616 to 1350 | 12 to 756 | | | | 745/914 (81 %) | 24 diff (97.4 %id) |
BG055447 | carcinoid, lung | HNRPLL.d | 1 to 295 | 1 to 295 | | tiling clone, | Submitted on the opposite strand | 295/295 (100 %) | 2 diff (99.4 %id) |
AW016143 | | HNRPLL.d | 2 to 342 | 16 to 357 | | | Submitted on the opposite strand | 342/357 (95 %) | 2 diff (99.5 %id) |
BE220027 | carcinoid, lung | HNRPLL.d | 5 to 461 | 1 to 457 | | | Submitted on the opposite strand | 457/457 (100 %) | 1 diff (99.8 %id) |
BG722713 | testis | HNRPLL.d | 175 to 834 | 1 to 659 | | tiling clone, | | 659/659 (100 %) | 6 diff (99.1 %id) |
AL512692 | lymph node | HNRPLL.d | 769 to 2957 | 1 to 2189 | | tiling clone, available from DKFZ, AAA | | 2189/2189 (100 %) | 0 diff (100 %id) |
BQ225947 | large cell carcinoma, lung | HNRPLL.d | 1030 to 1755 | 1 to 733 | | | | 733/864 (84 %) | 13 diff (98.5 %id) |
BQ218989 | leiomyosarcoma, uterus | HNRPLL.d | 2878 to 3890 | 1 to 1022 | | tiling clone, | | 1022/1022 (100 %) | 19 diff (98.2 %id) |
DN916265 | | HNRPLL.d | 2967 to 3052 | 1 to 87 | | | | 87/87 (100 %) | 2 diff (97.8 %id) |
AI342819 | carcinoid, lung | HNRPLL.d | 2987 to 3383 | 1 to 397 | | | Submitted on the opposite strand | 397/397 (100 %) | 1 diff (99.8 %id) |
DB511912 | testis | HNRPLL.d | 3001 to 3281 | 1 to 278 | | | Submitted on the opposite strand | 278/278 (100 %) | 21 diff (92.5 %id) |
BG622548 | placenta | HNRPLL.d | 3082 to 3917 | 1 to 859 | | tiling clone, | | 859/879 (97 %) | 38 diff (95.7 %id) |
BQ949097 | leiomyosarcoma, uterus | HNRPLL.e | 1 to 743 | 1 to 751 | | tiling clone, | | 751/881 (85 %) | 15 diff (98.3 %id) |
T82806 | liver and spleen | HNRPLL.e | 679 to 994 | 9 to 326 | | | | 318/326 (97 %) | 6 diff (98.2 %id) |
W05178 | liver and spleen | HNRPLL.e | 679 to 1082 | 9 to 418 | | tiling clone, | | 410/432 (94 %) | 6 diff (98.7 %id) |
DA471841 | | HNRPLL.e | 1685 to 2260 | 2 to 577 | | tiling clone, capped | | 576/576 (100 %) | 0 diff (100 %id) |
N75945 | liver and spleen | HNRPLL.e | 1781 to 2154 | 377 to 1 | | | | 377/377 (100 %) | 6 diff (98.5 %id) |
T89983 | liver and spleen | HNRPLL.e | 1896 to 2154 | 268 to 10 | | | | 259/268 (96 %) | 0 diff (100 %id) |
CR735975 | | HNRPLL.e | 2109 to 2779 | 1 to 671 | | tiling clone, | | 671/682 (98 %) | 1 diff (99.9 %id) |
DB314761 | | HNRPLL.e | 3141 to 3704 | 565 to 1 | | tiling clone, | | 565/565 (100 %) | 2 diff (99.7 %id) |
BP370573 | testis | HNRPLL.f | 1 to 568 | 1 to 568 | | tiling clone, | | 568/570 (99 %) | 1 diff (99.9 %id) |
DB262672 | uterus | HNRPLL.f | 384 to 926 | 2 to 545 | | tiling clone, capped | | 544/544 (100 %) | 1 diff (99.9 %id) |
DA469910 | | HNRPLL.g | 1 to 569 | 2 to 570 | exact | tiling clone, capped | | 569/569 (100 %) | 0 diff (100 %id) |
BE328148 | carcinoid, lung | HNRPLL.h | 1 to 512 | 512 to 1 | exact | tiling clone, | | 512/512 (100 %) | 0 diff (100 %id) |
BE178222 | head_neck | HNRPLL.h | 484 to 770 | 1 to 285 | | tiling clone, | | 285/294 (96 %) | 8 diff (97.3 %id) |
CR737836 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.h | 640 to 1295 | 1 to 656 | | tiling clone, AAA | Possibly primed on the genome, locally A rich (12/13 A in genome downstream of last aligned base) | 656/656 (100 %) | 0 diff (100 %id) |
AA946890 | 2 pooled tumors (clear cell type), Kidney | HNRPLL.h | 855 to 1304 | 449 to 1 | | tiling clone, | | 449/449 (100 %) | 1 diff (99.8 %id) |
L43338 | colon tumor | HNRPLL.h | 951 to 1130 | 1 to 176 | | | | 176/180 (97 %) | 13 diff (92.8 %id) |
DW408660 | Liver | HNRPLL.i | 1 to 325 | 17 to 342 | S29A E47K K61R H65R Q69H ... | tiling clone, | | 326/342 (95 %) | 13 diff (96.2 %id) |
AA514870 | colon | HNRPLL.j | 1 to 444 | 443 to 1 | V13A V17A D28A T66R A67H ... | tiling clone, | | 443/443 (100 %) | 6 diff (98.7 %id) |
CV365914 | nervous_normal | HNRPLL.j | 299 to 517 | 221 to 3 | | tiling clone, | Submitted on the opposite strand | 219/232 (94 %) | 0 diff (100 %id) |
TI_154009169 | | HNRPLL.k | 1 to 462 | 583 to 122 | exact | AAA | | 462/863 (53 %) | 0 diff (100 %id) |
CA435187 | lung, Metastatic Chondrosarcoma | HNRPLL.k | 1 to 462 | 480 to 19 | exact | tiling clone, AAA | | 462/474 (97 %) | 0 diff (100 %id) |
DA104704 | cerebellum | HNRPLL.l-u | 1 to 560 | 2 to 561 | exact | tiling clone, capped | | 560/560 (100 %) | 2 diff (99.7 %id) |
AA704556 | liver and spleen | HNRPLL.l-u | 195 to 547 | 1 to 353 | | | Submitted on the opposite strand | 353/353 (100 %) | 0 diff (100 %id) |
BF993209 | placenta_normal | HNRPLL.l-u | 448 to 924 | 492 to 18 | | tiling clone, | | 475/511 (92 %) | 0 diff (100 %id) |
BF999402 | placenta_normal | HNRPLL.l-u | 471 to 981 | 64 to 576 | | tiling clone, | | 513/576 (89 %) | 6 diff (99.0 %id) |
BQ720802 | sympathetic trunk | HNRPLL.l-u | 1289 to 2174 | 1 to 892 | | tiling clone, | | 892/893 (99 %) | 15 diff (98.4 %id) |
FN049302 | breast carcinoma | HNRPLL.l-u | 1393 to 1519 | 1 to 128 | | | | 128/128 (100 %) | 1 diff (99.3 %id) |
AI016467 | | HNRPLL.l-u | 1404 to 1835 | 433 to 2 | | | | 432/433 (99 %) | 0 diff (100 %id) |
R68386 | placenta | HNRPLL.l-u | 1494 to 1879 | 1 to 396 | | | | 396/401 (98 %) | 13 diff (96.8 %id) |
TI_149303485 | | HNRPLL.l-u | 1565 to 2411 | 916 to 73 | | AAA | | 844/973 (86 %) | 18 diff (98.2 %id) |
CN429839 | embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 | HNRPLL.l-u | 1603 to 1969 | 1 to 367 | | | | 367/367 (100 %) | 0 diff (100 %id) |
BF814741 | colon_ins | HNRPLL.l-u | 1612 to 2210 | 612 to 14 | | | Submitted on the opposite strand | 599/677 (88 %) | 0 diff (100 %id) |
BF245423 | brain, glioblastoma | HNRPLL.l-u | 1618 to 2294 | 1 to 671 | | | | 671/862 (77 %) | 22 diff (97.5 %id) |
BM981493 | lung, Primary Lung Cystic Fibrosis EpithelialCells | HNRPLL.l-u | 1701 to 2411 | 729 to 19 | | tiling clone, AAA | | 711/711 (100 %) | 2 diff (99.8 %id) |
DB299406 | cerebellum | HNRPLL.l-u | 1851 to 2411 | 563 to 1 | | | | 563/563 (100 %) | 10 diff (98.3 %id) |
DN916266 | | HNRPLL.l-u | 1874 to 2419 | 546 to 1 | | | | 546/546 (100 %) | 6 diff (99.0 %id) |
AK092622 | Prostate | HNRPLL.l-u | 1876 to 4317 | 1 to 2442 | | tiling clone, available from FLJ, | | 2442/2442 (100 %) | 5 diff (99.8 %id) |
DA872580 | Prostate | HNRPLL.l-u | 1877 to 2406 | 2 to 533 | | capped | | 532/532 (100 %) | 4 diff (99.3 %id) |
BF061515 | pooled | HNRPLL.l-u | 1942 to 2411 | 485 to 16 | | AAA | | 470/470 (100 %) | 1 diff (99.8 %id) |
BF055374 | pooled | HNRPLL.l-u | 1942 to 2412 | 472 to 2 | | | | 471/472 (99 %) | 0 diff (100 %id) |
BE856931 | pooled | HNRPLL.l-u | 1959 to 2411 | 467 to 15 | | AAA | | 453/453 (100 %) | 2 diff (99.6 %id) |
R68591 | placenta | HNRPLL.l-u | 2022 to 2411 | 403 to 1 | | | | 403/403 (100 %) | 28 diff (93.1 %id) |
DB558898 | hypothalamus | HNRPLL.l-u | 2052 to 2499 | 1 to 450 | | | Submitted on the opposite strand | 450/450 (100 %) | 2 diff (99.6 %id) |
AW611854 | Kidney | HNRPLL.l-u | 2177 to 2421 | 247 to 3 | | | | 245/247 (99 %) | 0 diff (100 %id) |
DB330001 | Prostate | HNRPLL.l-u | 3757 to 4317 | 564 to 1 | | | | 564/564 (100 %) | 4 diff (99.3 %id) |
BM926894 | brain | HNRPLL.m-u | 1 to 739 | 18 to 757 | exact | tiling clone, | | 740/790 (93 %) | 2 diff (99.8 %id) |
CD704287 | normal nasopharynx | HNRPLL.m-u | 452 to 933 | 15 to 496 | | tiling clone, | | 482/496 (97 %) | 6 diff (98.8 %id) |
BG400885 | Kidney | HNRPLL.n-u | 1 to 670 | 1 to 662 | exact | tiling clone, | | 662/924 (71 %) | 21 diff (97.8 %id) |
AW467747 | myeloid cells, 18 pooled CML cases, BCR/ABLrearrangement positive, includes both chronic phase andmyeloid blast crisis, whole blood | HNRPLL.n-u | 246 to 703 | 458 to 1 | | tiling clone, | | 458/458 (100 %) | 0 diff (100 %id) |
BI850998 | pooled | HNRPLL.o-u | 1 to 410 | 409 to 1 | exact | tiling clone, | | 409/418 (97 %) | 1 diff (99.8 %id) |
AA992185 | | HNRPLL.o-u | 79 to 408 | 337 to 8 | exact | tiling clone, | | 330/337 (97 %) | 0 diff (100 %id) |
BG818762 | anaplastic oligodendroglioma with 1p/19qloss, brain | HNRPLL.o-u | 87 to 407 | 13 to 333 | exact | tiling clone, AAA | | 321/333 (96 %) | 6 diff (98.2 %id) |
AA213774 | germinal center B cell | HNRPLL.o-u | 186 to 406 | 227 to 3 | | | | 225/231 (97 %) | 0 diff (100 %id) |
AY236962 | | Gene HNRPLL, variant not shown | | | | | Suspected internal deletion, this clone was ignored | | |
AY236963 | | Gene HNRPLL, variant not shown | | | | | Suspected internal deletion, suspected internal deletion, this clone was ignored | | |
BC008217 | Placenta, choriocarcinoma | Gene HNRPLL, variant not shown | | | | available from MGC, AAA | | | |
BE090473 | breast | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
DA119813 | cerebellum | Gene HNRPLL, variant not shown | | | | capped | Suspected internal deletion, this clone was ignored | | |
DA152845 | amygdala | Gene HNRPLL, variant not shown | | | | capped | This clone was ignored | | |
DA385467 | thalamus | Gene HNRPLL, variant not shown | | | | capped | This clone was ignored | | |
BX093120 | placenta | Gene HNRPLL, variant not shown | | | | | Submitted on the opposite strand | | |
AV715493 | | Gene HNRPLL, variant not shown | | | | | Suspected internal deletion, suspected internal deletion, this clone was ignored | | |
DA521277 | brain | Gene HNRPLL, variant not shown | | | | capped | Suspected internal deletion, suspected internal deletion, this clone was ignored | | |
FN081243 | breast carcinoma | Gene HNRPLL, variant not shown | | | | | | | |
AV696447 | hepatocellular carcinoma | Gene HNRPLL, variant not shown | | | | | Suspected internal deletion, this clone was ignored | | |
AV698622 | hepatocellular carcinoma | Gene HNRPLL, variant not shown | | | | | Suspected internal deletion, this clone was ignored | | |
DB500287 | hypothalamus | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
DB503294 | hypothalamus | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
H95173 | placenta | Gene HNRPLL, variant not shown | | | | | Submitted on the opposite strand | | |
AA833808 | germinal center B cell | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
AI193584 | lung | Gene HNRPLL, variant not shown | | | | | Submitted on the opposite strand | | |
AI475191 | colon, moderately-differentiated adenocarcinoma | Gene HNRPLL, variant not shown | | | | | | | |
AI819246 | lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) | Gene HNRPLL, variant not shown | | | | | Submitted on the opposite strand | | |
BQ028353 | mixed | Gene HNRPLL, variant not shown | | | | AAA | | | |
BF314828 | brain, neuroblastoma | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
DB322981 | | Gene HNRPLL, variant not shown | | | | | This clone was ignored | | |
DA687170 | | Gene HNRPLL, variant not shown | | | | capped | This clone was ignored | | |
DA760455 | | Gene HNRPLL, variant not shown | | | | capped | Suspected internal deletion, this clone was ignored | | |
TI_1948228650 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948228651 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948228652 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948228952 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948228953 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948229259 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948229560 | | Gene HNRPLL, variant not shown | | | | | | | |
TI_1948229562 | | Gene HNRPLL, variant not shown | | | | | | | |
DB226828 | trachea | Gene HNRPLL, variant not shown | | | | capped | | | |
DB349745 | trachea | Gene HNRPLL, variant not shown | | | | | | | |
CB529631 | Aveolar Macrophage, lung | Gene HNRPLL, variant not shown | | | | AAA | | | |
? | Gene Summary |
Gene on genome |
mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j, .k, .l-u, .m-u, .n-u, .o-u |
Alternative mRNAs features, proteins, introns, exons, sequences |
Expression Tissue |
Function, regulation, related genes CI |
To mine knowledge about the gene, please click the 'Gene Summary' or the 'Function, regulation, related genes ' tab at the top of the page. The 'Gene Summary' page includes all we learnt about the gene, functional annotations of neighboring genes, maps, links to other sites and the bibliography. The 'Function, regulation, related genes ' page includes Diseases (D), Pathways, GO annotations, conserved domains (C), interactions (I) reference into function, and pointers to all genes with the same functional annotation.
To compare alternative variants, their summarized annotations, predicted proteins, introns and exons, or to access any sequence, click the 'Alternative mRNAs features' tab. To see a specific mRNA variant diagram, sequence and annotation, click the variant name in the 'mRNA' tab. To examine expression data from all cDNAs clustered in this gene by AceView, click the 'Expression tissue'.
If you know more about this gene, or found errors, please share your knowledge. Thank you !